Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Waldenström macroglobulinemia is often slow growing, with a 78% five-year survival rate, but chronic conditions can affect ...

Three of five patients with advanced colorectal cancer responded to leronlimab, including one complete response lasting five years, according to new data.

T cells are a natural part of the immune system designed to fight infections and cancer, but in conditions like blood cancer, they may not be able to eliminate malignant cells, according to Dr.